144 related articles for article (PubMed ID: 12041852)
21. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
[TBL] [Abstract][Full Text] [Related]
22. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
Dingli D; Larson DR; Plevak MF; Grande JP; Kyle RA
Am J Kidney Dis; 2005 Aug; 46(2):278-82. PubMed ID: 16112046
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal gammopathy of undetermined significance versus smoldering myeloma: is active surveillance enough?
Jordan WE; Emmons R; Vogl D; Morris GJ
Semin Oncol; 2011 Jun; 38(3):327-34. PubMed ID: 21600358
[No Abstract] [Full Text] [Related]
24. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance.
Dizdar O; Erman M; Cankurtaran M; Halil M; Ulger Z; Yavuz BB; Ariogul S; Pinar A; Harputluoglu H; Kars A; Celik I
Ann Hematol; 2008 Jan; 87(1):57-60. PubMed ID: 17874101
[TBL] [Abstract][Full Text] [Related]
25. Vitritis and retinal vasculitis as presenting signs of monoclonal gammopathy of unknown significance with progression to multiple myeloma.
Chan TY; Hodge WG
Can J Ophthalmol; 2010 Feb; 45(1):82-3. PubMed ID: 20130722
[No Abstract] [Full Text] [Related]
26. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study.
Thompson MA; Kyle RA; Melton LJ; Plevak MF; Rajkumar SV
Haematologica; 2004 May; 89(5):626-8. PubMed ID: 15136236
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal gammopathy of undetermined significance.
Clark KT
J Insur Med; 1997; 29(2):136-8. PubMed ID: 10169631
[TBL] [Abstract][Full Text] [Related]
28. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
[TBL] [Abstract][Full Text] [Related]
29. [The monitoring of protein-volemic indices during plasmapheresis in patients with paraproteinemic hemoblastoses].
Kalinin NN; Movshev BE; Petrov MM; Petrova VI; Droshneva VA; Varlamova SV; Khoroshko ND; Zhuravlev VS; Loginov SP
Ter Arkh; 1996; 68(7):62-5. PubMed ID: 8928075
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in malignant transformation of monoclonal gammopathy of undetermined significance.
Adami F; Bortolin M; Lestani M; Chilosi M; Semenzato G
Leuk Lymphoma; 2002 Aug; 43(8):1713-4. PubMed ID: 12400621
[No Abstract] [Full Text] [Related]
31. Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures.
Golombick T; Diamond T
Acta Haematol; 2008; 120(2):87-90. PubMed ID: 18852483
[No Abstract] [Full Text] [Related]
32. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
Bidet A; Marit G; Bérard AM
Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
34. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
35. [Management of monoclonal gammopathy].
Huijgens PC; Zweegman S
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1401-2. PubMed ID: 12174432
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.
Martín-Ayuso M; Almeida J; Pérez-Andrés M; Cuello R; Galende J; González-Fraile MI; Martín-Nuñez G; Ortega F; Rodríguez MJ; San Miguel JF; Orfao A
Oncologist; 2008 Jan; 13(1):82-92. PubMed ID: 18245015
[TBL] [Abstract][Full Text] [Related]
37. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
38. A monoclonal gammopathy precedes multiple myeloma in most patients.
Weiss BM; Abadie J; Verma P; Howard RS; Kuehl WM
Blood; 2009 May; 113(22):5418-22. PubMed ID: 19234139
[TBL] [Abstract][Full Text] [Related]
39. [Cerebrospinal fluid proteins in 3 cases of polyneuritis complicating plasma cell dyscrasias].
Merelli E; Sola P; Galassi G; Gibertoni M; Colombo A; Shoenhuber R
Riv Neurobiol; 1984; 30(2-3):240-8. PubMed ID: 6544480
[No Abstract] [Full Text] [Related]
40. TGF-beta 1 and urinary excretion of pyridinium crosslinks: Two often overlooked risk factors for assessing risk of progression in patients with monoclonal gammopathy of undetermined significance.
Kapoor S
Haematologica; 2008 Mar; 93(3):e38. PubMed ID: 18310534
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
